Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study (Neurology and Therapy, (2024), 13, 3, (611-624), 10.1007/s40120-024-00591-z)

Barbanti, P.; Egeo, G.; Proietti, S.; D'Onofrio, F.; Aurilia, C.; Finocchi, C.; Di Clemente, L.; Zucco, M.; Doretti, A.; Messina, S.; Autunno, M.; Ranieri, A.; Carnevale, A.; Colombo, B.; Filippi, M.; Tasillo, M.; Rinalduzzi, S.; Querzani, P.; Sette, G.; Forino, L.; Zoroddu, F.; Robotti, M.; Valenza, A.; Camarda, C.; Borrello, L.; Aguggia, M.; Viticchi, G.; Tomino, C.; Fiorentini, G.; Orlando, B.; Bonassi, S.; Torelli, P.

doi:10.1007/s40120-024-00648-z

In Fig. 2d of this article the values of HIT-6 at week 12 for CM and HFEM were swapped. The correct values are as follows and the figure should have appeared as shown below. HIT-6: week 12 HFEM corresponds to − 18.1 HIT-6: week 12 CM corresponds to − 22.5 (Figure presented.) Fig. 2d Headache Impact Test-6 (HIT-6) score from baseline to week 48 in patients affected by high-frequency episodic migraine (HFEM, n = 49) or chronic migraine (CM, n = 81) The original article has been corrected.

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study (Neurology and Therapy, (2024), 13, 3, (611-624), 10.1007/s40120-024-00591-z) / Barbanti, P.; Egeo, G.; Proietti, S.; D'Onofrio, F.; Aurilia, C.; Finocchi, C.; Di Clemente, L.; Zucco, M.; Doretti, A.; Messina, S.; Autunno, M.; Ranieri, A.; Carnevale, A.; Colombo, B.; Filippi, M.; Tasillo, M.; Rinalduzzi, S.; Querzani, P.; Sette, G.; Forino, L.; Zoroddu, F.; Robotti, M.; Valenza, A.; Camarda, C.; Borrello, L.; Aguggia, M.; Viticchi, G.; Tomino, C.; Fiorentini, G.; Orlando, B.; Bonassi, S.; Torelli, P.. - In: NEUROLOGY AND THERAPY. - ISSN 2193-8253. - 13:5(2024), pp. 1505-1506. [10.1007/s40120-024-00648-z]